{"id":483342,"date":"2020-05-08T13:04:01","date_gmt":"2020-05-08T13:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483342"},"modified":"2020-05-08T13:04:01","modified_gmt":"2020-05-08T13:04:01","slug":"metabolic-acidosis-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metabolic-acidosis-market-insights-epidemiology-and-market-forecast2030_483342.html","title":{"rendered":"Metabolic Acidosis Market Insights, Epidemiology, and Market Forecast-2030"},"content":{"rendered":"
\"Metabolic<\/a><\/p>\n
\n
DelveInsight<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Metabolic Acidosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Metabolic Acidosis, historical and forecasted epidemiology as well as the Metabolic Acidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Metabolic Acidosis Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

DelveInsight launched a new report on Metabolic Acidosis Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

Some of the key facts of the report<\/span>
1. Metabolic Acidosis prevalence is approximately 15–19% in Chronic Kidney Disease stage 3–5 patients, with metabolic acidosis affecting approximately 3 million patients with Chronic Kidney Disease in the United States.<\/span>
2. A significant increase in the metabolic acidosis prevalence in patients with Chronic Kidney Disease stage 4 (44% of patients) and with Chronic Kidney Disease stage 5 (63% of patients) compared to patients with Chronic Kidney Disease stage 1 (10% of patients).<\/span><\/p>\n

Key benefits of the report<\/span>
1. Metabolic Acidosis market report covers a descriptive overview and comprehensive insight of the Metabolic Acidosis epidemiology and Metabolic Acidosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Metabolic Acidosis market report provides insights on the current and emerging therapies.<\/span>
3. Metabolic Acidosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Metabolic Acidosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metabolic Acidosis market.<\/span><\/p>\n

Request for sample pages<\/a><\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n

“Females are most commonly affected in case of Metabolic acidosis.”<\/span><\/p>\n

At present, there are no FDA approved therapies for the chronic treatment of metabolic acidosis, and there are several treatments that can be effective in metabolic acidosis, but still, there are many unmet needs. So, there is an immediate need for R&D activities for the development of novel therapies that can treat the root cause of the disease. A new drug candidate, called Veverimer (Tricida), may treat metabolic acidosis safely and effectively, and do so by removing accumulated acid from the gut without entering the bloodstream.<\/span><\/p>\n

Approximately 70-80% of patients are undiagnosed with stage 3 to 5 Chronic Kidney Disease and metabolic acidosis (serum bicarbonate < 22 mEq\/L)*, several Metabolic Acidosis treatments can be useful, but still, there are many unmet needs. So, there is an immediate need for R&D activities for the development of novel therapies that can treat the root cause of the disease; this further highlight the under Metabolic Acidosis treatment and the therapeutic gap.<\/span><\/p>\n

The definitive proof is lacking for optimal evidence-based practice guidelines. Ongoing trials will hopefully facilitate more evidence-based Metabolic Acidosis treatment in the future. Metabolic acidosis therapies have potential growth in upcoming years due to factors such as disease-modifying potential; no FDA approved product competition and huge underdiagnosed and undertreated patient pool.<\/span><\/p>\n

The other factors that shall further expedite metabolic acidosis market growth that includes increasing morbidity rate of metabolic acidosis and increasing awareness about available Metabolic Acidosis treatments during the forecast period (2019–2030).<\/span><\/p>\n

The launch of the emerging therapies is expected to significantly impact the Metabolic Acidosis treatment scenario in the upcoming years:-<\/span>
Drugs covered<\/span>
1. Veverimer<\/span>
2. ADV7103<\/span>
And many others<\/span><\/p>\n

The key players in Metabolic Acidosis market are:<\/span><\/p>\n

1. Tricida<\/span>
2. Advicenne<\/span>
And many others<\/span><\/p>\n

Table of contents<\/span>
1. Report Introduction<\/span>
2. Executive Summary<\/span>
3. SWOT analysis<\/span>
4. Metabolic Acidosis Patient Share (%) Overview at a Glance<\/span>
5. Metabolic Acidosis Market Overview at a Glance<\/span>
6. Metabolic Acidosis Disease Background and Overview<\/span>
7. Metabolic Acidosis Epidemiology and Patient Population<\/span>
8. Country-Specific Patient Population of Metabolic Acidosis<\/span>
8.1. United States<\/span>
8.2. EU5<\/span>
8.2.1. Germany<\/span>
8.2.2. France<\/span>
8.2.3. Italy<\/span>
8.2.4. Spain<\/span>
8.2.5. United Kingdom<\/span>
8.3. Japan<\/span>
9. Metabolic Acidosis Current Treatment and Medical Practices<\/span>
10. Unmet Needs<\/span>
11. Metabolic Acidosis Emerging Therapies<\/span>
11.1. Key Cross Competition<\/span>
11.2. Veverimer: Tricida<\/span>
11.3. ADV7103: Advicenne<\/span>
12. Metabolic Acidosis Market Outlook<\/span>
13. Country-Wise Metabolic Acidosis Market Analysis (2017–2030)<\/span>
13.1. United States Market Size<\/span>
13.2. Germany Market Size<\/span>
13.3. France Market Size<\/span>
13.4. Italy Market Size<\/span>
13.5. Spain Market Size<\/span>
13.6. United Kingdom Market Size<\/span>
13.7. Japan Market Size<\/span>
14. Market Access and Reimbursement of Therapies<\/span>
15. Market drivers<\/span>
16. Market barriers<\/span>
17. Appendix<\/span>
18. Metabolic Acidosis Report Methodology<\/span>
19. DelveInsight Capabilities<\/span>
20. Disclaimer<\/span>
21. About DelveInsight<\/span><\/p>\n

About DelveInsight<\/span>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight’s “Metabolic Acidosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Metabolic Acidosis, historical and forecasted epidemiology as well as the Metabolic Acidosis market trends in the United States, EU5 (Germany, Spain, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-483342","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483342"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483342\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}